Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-10-28 4:03 pm Purchase | 13G | ONKURE THERAPEUTICS, INC. CLAS OKUR | Octagon Capital Advisors LP | 225,000 1.800% | 225,000 (New Position) | View |
| 2024-10-11 4:02 pm Purchase | 13G | Allovir Inc. ALVR | Octagon Capital Advisors LP | 11,202,000 9.700% | 11,202,000 (New Position) | View |
| 2024-10-11 4:02 pm Purchase | 13G | ARRIVENT BIOPHARMA INC AVBP | Octagon Capital Advisors LP | 1,976,387 5.900% | 1,976,387 (New Position) | View |
| 2024-10-11 4:02 pm Purchase | 13G | CORBUS PHARMACEUTICALS HOLDING CRBP | Octagon Capital Advisors LP | 1,115,000 9.300% | 1,115,000 (New Position) | View |
| 2024-10-11 4:02 pm Purchase | 13G | DIANTHUS THERAPEUTICS INC DNTH | Octagon Capital Advisors LP | 1,746,667 6.000% | 1,746,667 (New Position) | View |
| 2024-10-11 4:02 pm Purchase | 13G | REGULUS THERAPEUTICS INC P RGLS | Octagon Capital Advisors LP | 4,263,701 6.500% | 4,263,701 (New Position) | View |
| 2024-10-11 4:02 pm Purchase | 13G | UNICYCIVE THERAPEUTICS INC UNCY | Octagon Capital Advisors LP | 8,559,000 9.100% | 8,559,000 (New Position) | View |
| 2024-08-28 4:02 pm Sale | 13G | AN2 Therapeutics Inc. ANTX | Octagon Capital Advisors LP | 0 0.000% | -3,009,927 (Position Closed) | View |
| 2024-07-03 08:02 am Purchase | 13G | AN2 Therapeutics Inc. ANTX | Octagon Capital Advisors LP | 3,009,927 10.100% | 3,009,927 (New Position) | View |
| 2024-02-06 4:04 pm Sale | 13G | Xilio Therapeutics Inc. XLO | Octagon Capital Advisors LP | 0 0.000% | -1,785,000 (Position Closed) | View |
| 2024-02-05 4:01 pm Purchase | 13G | ONKURE THERAPEUTICS, INC. CLAS OKUR | Octagon Capital Advisors LP | 2,250,000 6.750% | 2,250,000 (New Position) | View |
| 2024-02-05 4:01 pm Sale | 13G | Xilio Therapeutics Inc. XLO | Octagon Capital Advisors LP | 1,785,000 6.480% | -640,000 (-26.39%) | View |
| 2023-01-25 4:01 pm Purchase | 13G | Xilio Therapeutics Inc. XLO | Octagon Capital Advisors LP | 2,425,000 8.830% | 2,425,000 (New Position) | View |